FFA
NRIX icon

Founders Financial Alliance’s Nurix Therapeutics NRIX Stock Holding History

Founders Financial Alliance’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-18
Closed -$1K – 966
2020
Q3 		$1K Buy
+18
New +$454 ﹤0.01% 1300

Other funds holding NRIX

TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Founders Financial Alliance's NRIX Position: Q4 2020 in Review

Founders Financial Alliance sold out of Nurix Therapeutics (NRIX) in Q4 2020, closing a stake of 18 shares — an estimated $1K sold.

Founders Financial Alliance first reported a position in NRIX in Q3 2020 and held it in 1 quarter. The position peaked at $1K in Q3 2020. 68 funds tracked by Wall St. Rank hold NRIX as of Q4 2020.

  • Founders Financial Alliance reported no remaining Nurix Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Founders Financial Alliance sold 18 Nurix Therapeutics shares in Q4 2020, an estimated $1K.
  • Founders Financial Alliance first reported a position in Nurix Therapeutics in Q3 2020 and held it in 1 quarter.
  • Founders Financial Alliance's Nurix Therapeutics position peaked at $1K in Q3 2020.
  • 68 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q4 2020.

Based on Founders Financial Alliance's 13F filing for Q4 2020, filed 4 Feb 2021.